Moderna misses on 3Q, shaves 2022 vaccine expectations
Sliding COVID-19 vaccine sales and rising expenses for Moderna combined to produce a third quarter that missed Wall Street expectations. |!| Pawtucket
Sliding COVID-19 vaccine sales and rising expenses for Moderna combined to produce a third quarter that missed Wall Street expectations. |!| Pawtucket